Market Place
Sourcing Support
BPGbio Wins BioTech AI Company of the Year Award
19 Nov 2024 //
BUSINESSWIRE
BPGbio Present Immuno-Oncology Research on BPM31510 & BRG399 at SITC
07 Nov 2024 //
BUSINESSWIRE
BPGbio Receives FDA Rare Disease Designation for EB Treatment
31 Oct 2024 //
BUSINESSWIRE
BPGbio CEO to Present at Google Cancer AI Symposium
28 Oct 2024 //
BUSINESSWIRE
BPGbio Presents E2-based Targeted Protein Degradation Program
24 Oct 2024 //
BUSINESSWIRE
BPGbio Presents BPM31510 Data at MitoCon 2024
23 Oct 2024 //
BUSINESSWIRE
BPGbio Presents E2-Based Targeted Protein Degradation Approach
15 Oct 2024 //
BUSINESSWIRE
BPGbio CEO Named PharmaVoice 100 Winner For AI Drug Discovery
08 Oct 2024 //
BUSINESSWIRE
BPGbio And Oxford Enter Strategic Collaboration On Protein Research
07 Oct 2024 //
BUSINESSWIRE
BPGbio To Present Huntington`s And Alzheimer`s Findings
02 Oct 2024 //
BUSINESSWIRE
BPGbio Receives FDA Rare Pediatric Disease Designation
30 Sep 2024 //
BUSINESSWIRE
BPGbio And Joslin Publish Blue Light Fat Reduction Study
25 Sep 2024 //
BUSINESSWIRE
BPGbio Appoints John Beeler as SVP of Business Development
16 Sep 2024 //
BUSINESSWIRE
BPGbio Presents Glioblastoma Trial Update At ESMO Congress 2024
12 Sep 2024 //
BUSINESSWIRE
BPGbio To Present On E2-Based Targeted Protein Degradation At Drug Forum
26 Aug 2024 //
BUSINESSWIRE
BPGbio To Present Mitochondrial Medicine Research At EBEC 2024
19 Aug 2024 //
BUSINESSWIRE
BPGbio Adds Cancer Researcher Dr. Dipanjan Chowdhury To Advisory Board
08 Jul 2024 //
BUSINESSWIRE
BPGbio Sponsors Mitochondrial Medicine 2024 Conference
20 Jun 2024 //
BUSINESSWIRE
BPGbio Publishes Parkinson`s Diagnostic Biomarker Validation
20 May 2024 //
BUSINESSWIRE
BPGbio Bringing Late-Stage Assets To Pharma Partnering Summits
07 May 2024 //
BUSINESSWIRE
BPGbio Presents Key Advances in its Oncology Pipeline to the NAi Platform
05 Apr 2024 //
BUSINESSWIRE
BPGbio, and Cresa Announce 70,000-sq.-ft. Lease at 300 Third Avenue in Waltham
21 Feb 2024 //
BUSINESSWIRE
BPGbio Appoints Ritesh Srivastava as General Counsel
22 Jan 2024 //
BUSINESSWIRE
BPGbio Presents Updated Phase 2a Results Demonstrating Benefit of BPM31510
18 Jan 2024 //
BUSINESSWIRE
BPGbio Announces Phase 2 BPM31510 Glioblastoma Trial-in-Progress Update
16 Nov 2023 //
BUSINESSWIRE
BPGbio Wins BioTech Breakthrough Award for Therapeutics Platform of The Year
08 Nov 2023 //
BUSINESSWIRE
BPGbio Highlights AI-Developed Late-Stage Therapeutics Assets
07 Nov 2023 //
BUSINESSWIRE
BPGbio to Share in Development of Late-Stage AI-Developed Therapeutic Pipeline
10 Oct 2023 //
BUSINESSWIRE
BPGbio Appoints Vijay Modur, M.D., Ph.D., as SVP & Chief Medical Officer
02 Oct 2023 //
BUSINESSWIRE
BPGbio Announces Commercial Availability of NAi, BPGbio’s Platform
28 Sep 2023 //
BUSINESSWIRE
BPGbio & VELL Collaborate to Launch Revolutionary Global Health Initiative
25 Jul 2023 //
BUSINESSWIRE
BPGbio Announces Partnership with Grupo Terralpe
12 Jul 2023 //
BUSINESSWIRE
Dr. Robert Redfield Joins BPGbio Scientific Advisory Board
10 Jul 2023 //
BUSINESSWIRE
BPGbio Announces First Patients Dosed in Phase 2 Trial of AI-Developed BPM 31510
06 Jun 2023 //
BUSINESSWIRE
BPGbio Announces Partnership with AI-Guided Breast Cancer Diagnostics
22 May 2023 //
BUSINESSWIRE
BPGbio Announces Oncology Drug Pipeline at AACR
12 Apr 2023 //
BUSINESSWIRE
